Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699331 | 0.86 | TLR7 (0.54) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6702065 | 0.85 | TLR7 (0.49) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6107460 | 0.85 | TLR7 (0.55) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6695790 | 0.83 | TLR7 (0.51) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6694771 | 0.83 | TLR7 (0.51) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6730779 | 0.82 | TLR7 (0.52) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL14500910 | 0.81 | FGFR1 (0.31) | — | |
| SCHEMBL7180218 | 0.81 | TLR7 (0.54) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL544697 | 0.81 | TLR7 (0.48) | TLR7LMNANUDT1POLBHRH2 | |
| SCHEMBL6702071 | 0.80 | TLR7 (0.50) | TLR7LMNANUDT1POLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450804-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | claimed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | claimed |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | claimed |
| WO-2003045391-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | claimed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
| US-7968562-B2 | an immune response modifier (IRM) compound 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine; fatty acids such as oleic acid, isostearic acid; hydrophobic, aprotic caprylic/capric triglyceride miscible with fatty acid; actinic keratosis, postsurgical scars, warts, atopic dermatitis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1450804-B9 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080275077-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | SKWIERCZYNSKI RAYMOND D | 2008-11-06 | — | — | US | disclosed |
| EP-1450804-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6664260-B2 | Viricides; anticarcinogneic agents; induction cytokine biosynthesis | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | TLR7 35/4885LMNA 3958/4885NUDT1 844/4885 |
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | TLR7 35/4885LMNA 3901/4885NUDT1 1245/4885 |
| US-20080275077-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | ICOS, STAT6, INMT | TLR7 36/4885LMNA 3865/4885NUDT1 1261/4885 |
| US-20040072858-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | TLR7 35/4885LMNA 3958/4885NUDT1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.